{"id":40894,"date":"2026-03-29T11:20:09","date_gmt":"2026-03-29T11:20:09","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/40894\/"},"modified":"2026-03-29T11:20:09","modified_gmt":"2026-03-29T11:20:09","slug":"novartis-shares-bolstered-by-kidney-disease-therapy-milestone","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/40894\/","title":{"rendered":"Novartis Shares Bolstered by Kidney Disease Therapy Milestone"},"content":{"rendered":"

Novartis’s Fabhalta shows 49.3% slower kidney decline in IgA nephropathy trial, securing FDA Priority Review and bolstering its nephrology portfolio ahead of Q1 2026 results.<\/p>\n

Significant clinical trial results for Novartis’s drug Fabhalta, released this Sunday, indicate a potential shift in the standard of care for a rare kidney disorder. The data positions the pharmaceutical giant for an expedited regulatory review in the United States and strengthens its foundation in nephrology.<\/p>\n

Clinical Data Paves Way for Regulatory Advance<\/p>\n

The Phase III APPLAUSE-IgAN study demonstrated that Fabhalta slowed the decline of kidney function by 49.3% over two years when compared to a placebo. Furthermore, more than 40% of trial participants experienced a sustained reduction in protein levels in their urine. These findings, which have been published in the New England Journal of Medicine, suggest a considerable efficacy advantage over existing treatments for IgA nephropathy.<\/p>\n

In response to the robust trial outcomes, the U.S. Food and Drug Administration (FDA) has granted the application for full approval a Priority Review designation. Previously, Fabhalta held only a limited approval for reducing proteinuria. Securing a traditional approval is expected to solidify Novartis’s market standing and underscore the drug’s blockbuster potential.<\/p>\n

Should investors sell immediately? Or is it worth buying Novartis?<\/a><\/p>\n

Strategic Expansion and Financial Context<\/p>\n

Alongside this medical advancement, Novartis is pushing forward with a strategic expansion in Asia. The company has outlined plans to invest over 3.3 billion yuan (approximately $460 million) to enhance its research and production capabilities in Beijing. China has emerged as the second most important market for Novartis, forming a cornerstone of its long-term innovation strategy.<\/p>\n

Despite these operational developments, the positive momentum has not yet been fully reflected in the company’s share price. Trading closed on Friday at \u20ac129.00, marking a slight daily decrease of 0.23%. The current valuation sits roughly 9.8% below its 52-week high of \u20ac143.04, though it maintains a year-to-date gain of 9.68%.<\/p>\n

The newly released clinical data provides fundamental support for the equity’s valuation as the market looks ahead to the next key financial update. Novartis is scheduled to report its first-quarter results on April 28, 2026, which are anticipated to offer further insight into the financial impact of its new growth initiatives.<\/p>\n

Ad<\/p>\n

Novartis Stock: New Analysis – 29 March<\/p>\n

Fresh Novartis information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n

Read our updated Novartis analysis…<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novartis’s Fabhalta shows 49.3% slower kidney decline in IgA nephropathy trial, securing FDA Priority Review and bolstering its…\n","protected":false},"author":2,"featured_media":40895,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[23780,14592,23781,4008,4005,18119,206,8600,2220,9053],"class_list":["post-40894","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-bolstered","tag-disease","tag-fabhalta","tag-iga","tag-kidney","tag-milestone","tag-novartis","tag-novartiss","tag-shares","tag-therapy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116312200022946374","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/40894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=40894"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/40894\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/40895"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=40894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=40894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=40894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}